The team at MH were delighted to advise Accel and XTX Ventures as they co-led the Pre-Series A Investment into Turbine.
Turbine successfully raised €5.7M in the round, which also included new investor, Boston Millenia Partners, and existing investors Delin Ventures, Atlantic Labs and o2h Ventures.
The company develops an AI-enabled cell simulation technology to understand the complex biology of cancer. With the help of the Simulated Cell™, the team discovers novel targets, which have better chances of turning into clinical success than targets tested with wet-lab methods. This funding will be used to help Turbine advance its simulation-based pipeline to tackle the highest unmet needs in oncology.